Navigation Links
Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
Date:9/30/2009

SCHAUMBURG, Ill., Sept. 30 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. According to IMS, 2008 sales of vinorelbine injection, USP in the United States approximated $17 million. Sagent will begin marketing and shipping vinorelbine injection immediately.

"Sagent has launched six products in the third quarter of 2009, including vinorelbine, our third oncolytic product. Our innovative business model enables us to provide our customers with a broad range of products and delivery systems with features designed to help enhance safety and convenience," said Michael Logerfo, corporate vice president of Sagent. "We continue to receive positive feedback from our customers who often consider the enhanced features of our products to be important factors when making their purchasing decisions."

Sagent's vinorelbine injection is offered in 10 mg per 1 mL and 50 mg per 5 mL, latex-free and preservative-free, single-dose vials that incorporate easy-to-read product and dosage information.

About Vinorelbine Injection, USP

Vinorelbine injection is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, vinorelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, vinorelbine is indicated in combination with cisplatin.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
3. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
4. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
5. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
6. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
7. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
8. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
9. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
10. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
11. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016  Compass Diversified Holdings (NYSE: ... owner of leading middle market businesses, announced today its ... 31, 2016. First Quarter 2016 Highlights ... ("CAD" or "Cash Flow") of $13.6 million for the ... of $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... 2016 According to market research "Global ... Forecast to 2022 - Industry Insights by Slice Type (High, ... Others)" by P&S Market Research, the global computed tomography ... it is expected to grow at a CAGR of 5.0% ... segment is expected to witness the faster growth, CAGR of ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... Canadian author Mark Black is a ... Life From the Heart" around the world … with the help of his publisher Strategic ... 24, Mark Black lay in a hospital bed waiting for a miracle: He needed a ...
(Date:5/6/2016)... ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... he has found in the Bible about helping to stop cancer. Yisrayl says there are ... his hope that the health and science industries will pay close attention and take action. ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... David Konur, CEO of Cardiovascular Institute of the South announced today that Dr. ... a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. , ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession ... the impact our aging population has on communities and resources. Aging Life Care plays ... and face age-related challenges. , Aging Life Care is a holistic, client-centered approach ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food and ... e-cigarette manufacturers to submit their products through an arduous federal approval process. The ... that entered the market since February 15, 2007. That would essentially ban 99 ...
Breaking Medicine News(10 mins):